AKT1 and breast cancer: The recognition of enhanced Akt signaling in cancer, including breast cancer [87], has led to the development of novel agents targeting Akt, such as perifosine, BAY1125976, MK-2206, afuresertib, miransertib, and ipatasertib, all currently in clinical trials [88].